{
    "clinical_study": {
        "@rank": "5128", 
        "brief_summary": {
            "textblock": "The purpose of this research study is to test the safety and effectiveness of Interferon\n      gamma-1b (IFN-g 1b) injected subcutaneously (under the skin) for the treatment of advanced\n      liver fibrosis and cirrhosis in patients with chronic hepatitis C infections.\n\n      IFN-g 1b is not currently approved for the treatment of liver fibrosis."
        }, 
        "brief_title": "Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis", 
        "completion_date": {
            "#text": "November 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Liver Fibrosis", 
            "Cirrhosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Fibrosis", 
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C", 
                "Liver Cirrhosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will evaluate the safety and tolerability of IFN-g 1b in patients with advanced\n      liver fibrosis and cirrhosis due to hepatitis C.  This study will also evaluate whether\n      IFN-g 1b is effective in reducing the amount of fibrosis in the liver."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Men or women 18 to 75 years\n\n          -  Chronic hepatitis C infection based on a history of positive anti-HCV antibody and/or\n             HCV RNA\n\n          -  History of prior treatment with interferon-a-based therapies or an assessment by the\n             investigator that the patient would not benefit from interferon-a-based therapy or\n             that treatment with interferon-a is contraindicated\n\n          -  Stage 4, 5 or 6 liver fibrosis according to the Ishak scoring system.\n\n          -  Cannot have presence of clinically evident ascites requiring active diuretic therapy,\n             history of or therapy for hepatic encephalopathy, or history of GI variceal bleeding\n             within the last 2 years (diuretic therapy of stable mild-to-moderate peripheral edema\n             is permitted)\n\n          -  Must meet minimum blood chemistry requirements\n\n          -  Cannot have unstable or uncontrolled thyroid disease\n\n          -  Cannot have a variety of other diseases (listed in protocol\n\n          -  Other conditions for enrollment exist which would be discussed with a Clinician upon\n             screening for the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "502", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 7, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00043303", 
            "org_study_id": "GILF-001"
        }, 
        "intervention": {
            "description": "100 or 200 mcg, SQ, 3x per week", 
            "intervention_name": "interferon gamma-1b", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-gamma", 
                "Interferons"
            ]
        }, 
        "keyword": [
            "hepatitis C", 
            "liver fibrosis", 
            "liver cirrhosis"
        ], 
        "lastchanged_date": "October 29, 2007", 
        "number_of_arms": "1", 
        "official_title": "A Multicenter Study of the Safety and Anti-Fibrotic Efficacy of Interferon-Gamma 1b (Actimmune) in Patients With Severe Lever Fibrosis or Compensated Cirrhosis Due to Hepatitis C.", 
        "overall_official": {
            "affiliation": "InterMune", 
            "last_name": "Steven Porter, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_outcome": {
            "measure": "Ishak fibrosis score", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00043303"
        }, 
        "source": "InterMune", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InterMune", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2007"
    }, 
    "geocoordinates": {}
}